USD
+$0.00
(+0.00%
)At Close (As of Sep 3, 2025)
$209.35M
Market Cap
-
P/E Ratio
-3.84
EPS
$54.30
52 Week High
$2.29
52 Week Low
LIFE SCIENCES
Sector
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$16M |
Selling General And Administrative | $3.2B |
Research And Development | $13M |
Operating Expenses | $16M |
Investment Income Net | - |
Net Interest Income | $404K |
Interest Income | $404K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $16M |
Income Before Tax | -$16M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$16M |
Comprehensive Income Net Of Tax | - |
Ebit | -$32M |
Ebitda | -$16M |
Net Income | -$16M |
Field | Value (USD) |
---|---|
Total Assets | $60M |
Total Current Assets | $60M |
Cash And Cash Equivalents At Carrying Value | $46M |
Cash And Short Term Investments | $46M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $60B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | $14M |
Other Current Assets | $79K |
Other Non Current Assets | - |
Total Liabilities | $5.3M |
Total Current Liabilities | $5.3M |
Current Accounts Payable | $2.3M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $0 |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $3M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $55M |
Treasury Stock | - |
Retained Earnings | -$76B |
Common Stock | $6.1K |
Common Stock Shares Outstanding | $3.8M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$6.4M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | - |
Capital Expenditures | $0 |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$14M |
Cashflow From Financing | $59M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$16M |
Field | Value (USD) |
---|---|
Gross Profit | - |
Total Revenue | $0 |
Cost Of Revenue | - |
Costof Goods And Services Sold | - |
Operating Income | -$16M |
Selling General And Administrative | $3.2B |
Research And Development | $13M |
Operating Expenses | $16M |
Investment Income Net | - |
Net Interest Income | $404K |
Interest Income | $404K |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $16M |
Income Before Tax | -$16M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$16M |
Comprehensive Income Net Of Tax | - |
Ebit | -$32M |
Ebitda | -$16M |
Net Income | -$16M |
Sector: LIFE SCIENCES
Industry: PHARMACEUTICAL PREPARATIONS
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to developing proprietary therapies to improve clinical outcomes for cancer patients in the United States. The company is headquartered in Wilmette, Illinois.